

RECORDATI: PUBLIC DISCLOSURE

*Milan, 30 March 2020 – Please be informed that the **Directors' Report relating to item no. 2 (Integration of the Board of Directors after first changing the number of directors)** and the **Directors' Report relating to item no. 5 (Report on the remuneration policy and the remuneration paid)** of the agenda of the ordinary Shareholders' meeting called for 29th April 2020, together with the **Report on the 2020 Remuneration Policy and remuneration paid for 2019**, are available to the public, as of today, on the Company's website (www.recordati.it, the first and the second document in the Investors – Shareholders' Meeting section and the third in the Corporate Governance - Remuneration section) and on the "1info" storage mechanism (www.1info.it).*

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale

VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150
CODICE FISCALE/P. IVA 00748210150
R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l